← back to search
Eileen Stark
NewYork–Presbyterian Hospital ·
Area of research
Genetics · Neurology
Research interest
Research interests include Medicine, Alemtuzumab, Fludarabine, Cytarabine, and Internal medicine.
h-index
—
citations
62
works
1
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)
Blood
2022
cited by
62
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
Gail J. Roboz
· Cornell University
1
papers (2022–2022)
—
·
1
papers (2022–2022)
—
·
1
papers (2022–2022)
David A. Sallman
· Moffitt Cancer Center
1
papers (2022–2022)
Eunice S. Wang
· Roswell Park Comprehensive Cancer Center
1
papers (2022–2022)
Saar Gill
· Parker Institute for Cancer Immunotherapy
1
papers (2022–2022)
—
·
1
papers (2022–2022)
Shira Dinner
· Yale Cancer Center
1
papers (2022–2022)
—
·
1
papers (2022–2022)
Rebecca L. Olin
· UCSF Helen Diller Family Comprehensive Cancer Center
1
papers (2022–2022)
Daniel J. DeAngelo
· Harvard University
1
papers (2022–2022)
Naveen Pemmaraju
· The University of Texas MD Anderson Cancer Center
1
papers (2022–2022)
Daniel J. Lee
· Massachusetts Eye and Ear Infirmary
1
papers (2022–2022)
Asifa Haider
· Rockefeller University
1
papers (2022–2022)
Mark G. Frattini
· Roswell Park Comprehensive Cancer Center
1
papers (2022–2022)
Marina Konopleva
· Sidney Kimmel Comprehensive Cancer Center
1
papers (2022–2022)